Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model

EuroIntervention

Volumn 10, Issue 3, 2014, Pages 392-399

  Dai, Zixuan ^a   Yu, Shengbo ^a   Zhao, Qingyan ^a   Meng, Yanyan ^a   He, Huang ^a   Tang, Yanhong ^a   Wang, Xi ^a   Xiao, Jinping ^a   Wang, Xule ^a   Huang, Congxin ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Ablation; Heart failure; Remodelling; Renal sympathetic nerve; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; FEMALE; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; KIDNEY DENERVATION; LEFT VENTRICULAR DIASTOLIC DIMENSION; MALE; MONGREL DOG; NONHUMAN; PROTEIN EXPRESSION; RENAL SYMPATHETIC DENERVATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RIGHT VENTRICULAR DIASTOLIC DIMENSION; VENTRICULAR INTERSTITIAL FIBROSIS; VENTRICULAR SUBSTRATE REMODELLING; ANIMAL; ARRHYTHMIAS, CARDIAC; BLOOD; CATHETER ABLATION; DISEASE COURSE; DISEASE MODEL; DOG; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART PACING; HEART VENTRICLE; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; INNERVATION; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SYMPATHECTOMY; TIME;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; FEMALE; FIBROSIS; HEART FAILURE; HEART VENTRICLES; KIDNEY; MALE; NATRIURETIC PEPTIDE, BRAIN; SYMPATHECTOMY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 84905502950     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV10I3A65     Document Type: Article

References (32)

1. Vijayaraghavan K, Deedwania P. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin. 2011;29:137-56.
2. Jorde UP. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact. Cardiol Rev. 2006;14:81-7. (Pubitemid 44378512)
3. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002;105:393-6. (Pubitemid 34106191)
4. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res. 2003;26:691-7. (Pubitemid 37258655)
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685-91. Erratum in N Engl J Med. 1992;327:1768.
6. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-8.
7. Wang W, Zucker IH. Cardiac sympathetic afferent reflex in dogs with congestive heart failure. Am J Physiol. 1996;271:R751-6.
8. Wang W, Ma R. Cardiac sympathetic afferent reflexes in heart failure. Heart Fail Rev. 2000;5:57-71. (Pubitemid 30301511)
9. Ma R, Zucker IH, Wang W. Central gain of the cardiac sympathetic afferent reflex in dogs with heart failure. Am J Physiol. 1997:273: H2664-71.
10. Zhao Q, Yu S, Zou M, Dai Z, Wang X, Xiao J, Huang C. Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. J Interv Card Electrophysiol. 2012;35:119-25.
11. Sadoshima J, Izumo S. Molecular characterisation of angiotensin II - induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73:413-23. (Pubitemid 23238726)
12. Xia QG, Chung O, Spitznagel H, Illner S, Jänichen G, Rossius B, Gohlke P, Unger T. Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovasc Res. 2001;49:110-7.
13. Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst. 2004;5:S7-10.
14. Barlucchi L, Leri A, Dostal DE, Fiordaliso F, Tada H, Hintze TH, Kajstura J, Nadal-Ginard B, Anversa P. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res. 2001;88:298-304. (Pubitemid 32173753)
15. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75. (Pubitemid 33126822)
16. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71. (Pubitemid 37093916)
17. Zucker IH, Gorman AJ, Cornish KG, Lang M. Impaired atrial receptor modulation or renal nerve activity in dogs with chronic volume overload. Cardiovasc Res. 1985;19:411-8. (Pubitemid 15033669)
18. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-21. (Pubitemid 16081418)
19. Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol. 2011;300:F31-9.
20. DiBona GF, Sawin LL. Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol. 1991;260:R298-305.
21. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980;302:1373-9.
22. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-53. (Pubitemid 28036901)
23. Akar FG, Nass RD, Hahn S, Cingolani E, Shah M, Hesketh GG, DiSilvestre D, Tunin RS, Kass DA, Tomaselli GF. Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H1223-30. (Pubitemid 47254225)
24. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993;88:107-24. (Pubitemid 23226442)
25. Weber KT, Sun Y, Katwa LC, Cleutjens JP. Tissue repair and angiotensin II generated at sites of healing. Basic Res Cardiol. 1997;92:75-8. (Pubitemid 27198768)
26. Kupfahl C, Pink D, Friedrich K, Zurbrügg HR, Neuss M, Warnecke C, Fielitz J, Graf K, Fleck E, Regitz-Zagrosek V. Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res. 2000;46:463-75. (Pubitemid 30319332)
27. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, Takemiya K, Koga M, Yamamoto T, Imaizumi T. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension. 2004;43:499-503. (Pubitemid 38174161)
28. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Resource Utilization Among Congestive Heart Failure (REACH) Study. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60-9. (Pubitemid 34059862)
29. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effect on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-80.
30. Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA. 2002;287:883-9. (Pubitemid 34252037)
31. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet. 1990;336:1-6.
32. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-67.